Doxy-PEP could select for ceftriaxone resistance in Neisseria gonorrhoeae
Authors:
- 22 April 2025
- journal article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 25 (6) , e316
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Doxycycline to prevent bacterial sexually transmitted infections in the USA: final results from the DoxyPEP multicentre, open-label, randomised controlled trial and open-label extensionThe Lancet Infectious Diseases, 2025
- From Cure to Prevention: Doxycycline’s Potential in Prophylaxis for Sexually Transmitted InfectionsAntibiotics, 2024
- Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial designThe Lancet Infectious Diseases, 2024
- A Trial of Minocycline Given after Exposure to Prevent GonorrheaNew England Journal of Medicine, 1979